Clinical trials
Phase 3 Urologic Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Active, not recruiting | 4 |
| Terminated | 4 |
| Recruiting | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Astellas Pharma Europe Ltd. | 2 |
| Astellas Pharma Inc | 2 |
| Cook MyoSite | 2 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2 |
| Medical Enterprises Europe B.V. | 2 |
| Urovant Sciences GmbH | 2 |
| APOGEPHA Arzneimittel GmbH | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Biohaven Therapeutics Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urologic Diseases | 25 |
| Kidney Diseases | 7 |
| Urinary Bladder Diseases | 7 |
| Renal Insufficiency, Chronic | 6 |
| Glomerulonephritis | 5 |
| Glomerulonephritis, IGA | 5 |
| Neoplasms | 5 |
| Neoplasms by Site | 5 |
| Urinary Bladder Neoplasms | 5 |
| Urinary Bladder, Overactive | 5 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.